Cancer Vaccines Poised to Unlock 'New Treatment Paradigm' With Merck/Moderna Data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday.
With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago.
"Some of the residual uncertainty seems to be going away on that potential (option)," said Moderna President Stephen Hoge.
The data followed earlier promising data from the trial showing the customized mRNA vaccine given in combination with Merck's Keytruda cut the risk of death or recurrence of melanoma by 44% compared with Keytruda alone.
Wilt u de rest van dit artikel lezen?
Registreer gratis om toegang te krijgen tot de volledige inhoud van MediQuality op al uw schermen